Navigation Links
Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
Date:10/31/2013

EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO

The TreatmentTrends®: Type 2 Diabetes (U.S.) 2013 report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).

The report examines five products in development for the treatment of type 2 diabetes—Bristol-Myers Squibb/AstraZeneca's dapagliflozin, GlaxoSmithKline's albiglutide, Eli Lilly's dulaglutide, Novo Nordisk's Tresiba and Takeda's fasiglifam. After reviewing a product profile, surveyed endocrinologists indicated a higher mean interest level for the long-acting insulin Tresiba versus the SGLT-2 inhibitor dapagliflozin.

"The report focuses on physician perception of type 2 diabetes product satisfaction, attribute importance, product performance and sales representative frequency and performance," said BioTrends Research Group Director Rob Dubman. "For example, the study found that at least 40 percent of surveyed physicians have seen a sales representative in the past month across 11 products in the survey; however, physicians were more likely to see Novo Nordisk's NovoLog and Merck's Januvia sales representatives in the past month, compared with representatives from Bristol-Myers Squibb/AstraZeneca's Byetta and Onglyza."

TreatmentTrends®: Type 2 Diabetes 2013 is a syndicated report, based on primary market research of 102 U.S. Endocrinologists and 55 U.S. PCPs, which provides a comprehensive view of the current and expected future management of type 2 diabetes patients, which published in October 2013. This report, which is new to the Decision Resources Group portfolio, includes a market overview, referral patterns, patient demographics, current and anticipated patient share, average lines of treatment, number of weeks on therapy, attribute importance and product performance, product satisfaction, sales representative frequency and performance, message recall, statement agreements, future treatment and desirable attributes for new type 2 diabetes treatments, among many other topics.

Webinar
Members of the media are welcome to attend our upcoming webinar entitled Type 2 Diabetes in the United States—Clinical Practice in a Changing Market Landscape. This webinar will be held on November 19 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at ccomfort@dresources.com.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact: 

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
2. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
3. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
4. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
5. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
6. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
7. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
8. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
9. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
10. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
11. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):